Products
Lesofavumab Biosimilar Monoclonal Antibody (Influenza B Virus) for Research
Cat No.: GMP-Bios-ab-305
Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lesofavumab is a human immunoglobulin G1, antibody cloned from a single human plasmablast, isolated from an influenza-vaccinated donor.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-305-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody |
| INN Name | Lesofavumab |
| Target | Influenza B Virus |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Influenza B virus infections |
| Development Tech | na |
